Cover Image

Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts

Notice
This publication has been discontinued on February 26, 2013.

Abstract

Greystone Research Associates is pleased to announce the publication of a new market study. Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug developers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for diabetes drug therapeutics that do not derive from the administration of insulins or insulin analogs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

The Growing Demand and Evolving Landscape for Diabetes Management

The diabetes market is changing. The convergence of environmental factors, lifestyle factors and increased patient longevity are driving double-digit growth projections for the incidence of non-insulin dependent (Type 2) diabetes globally. Type 2 diabetes accounts for about 90% of all diagnosed cases of diabetes and is increasingly being diagnosed in children and adolescents. There are eight drug classes, analyzed in this report, with proven efficacy for aiding in glycemic control in this patient population. Because of the size and business potential of this market, pipeline activity is high. In addition to derivative products and products that combine approved APIs in a single dosage form, drugs based on newer chemistries and mechanisms that include amylin analogs and GLP-1 drugs have been introduced. Globally, revenues of drugs for managing Type 2 diabetes will grow by 14% between 2011 and 2016. Safety issues associated with post-launch-reported events will continue to be a major concern for market participants.

Highlights

  • Analyzes and evaluates non-insulin or insulin analog drug products and development-stage candidates for glycemic control
  • Provides assessments of diabetes managemnet markets for non-insulin drugsl and examines key market and commercialization factors
  • Evaluates the impact of economic, technology, and regulatory factors on diabetes management markets
  • Provides market data and forecasts to 2016
  • Profiles market sector participants, their product development activities and business strategies

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Table of Contents

Executive Summary

Diabetes Management Market Dynamics

  • The Economics of Diabetes
  • Therapeutic Options and Patient Outcomes
  • Evolving Healthcare Initiatives
  • Demand Drivers
  • Competitive Landscape
  • Risk Factors

Non-Insulin Diabetes Management - Product Development Factors

  • Formulation and Administration
    • Oral Form Factors
    • Injectable Formulations
      • Dosing Frequency
      • Injectable Device Strategies
  • Clinical Trial Factors
  • Combination Therapeutics

Non-Insulin Drug Therapeutics - Classes, Mechanisms and Prescribing Factors

  • Alpha-glucosidase Inhibitors
  • Amylin Analogs
  • Di-peptidyl peptidase IV
  • Glitazones (Thiazolidinediones)
  • Glucagon-Like Peptide-1 (GLP-1)
  • Metformin
  • Meglitinides
  • Sulfonylureas

Non-Insulin Drug Therapeutics - Commercial Product Assessments

  • Branded Drugs
    • Alpha-glucosidase Inhibitors
      • Glyset (Miglitol)
      • Precose (Acarbose)
    • Amylin Analogs
      • Symlin (pramlintide acetate)
    • Dipeptidyl peptidase IV
      • Januvia (Sitagliptin)
      • Onglyza (BMS)
      • Tradjenta (Linagliptin)
    • Glitazones (Thiazolidinediones)
      • Pioglitazones
      • Rosiglitazones
    • Glucagon-Like Peptide-1 (GLP-1)
      • Byetta (Amylin)
      • Bydureon (Amylin)
      • Victoza (NovoNordisk)
    • Meglitinides
      • Starlix (Nateglinide)
      • Prandin (Repaglinide)
    • Sulfonylureas
      • Glipizide
      • Glimepirides
    • Other Therapeutic Classes
      • Dopamine Receptor Agonists
    • Combination Drug Products
      • Actoplus Met (Takeda)
      • Avandamet (GloxoSmithKline)
      • Avandaryl (GlaxoSmithKline)
      • Duetact (Takeda)
      • Glucovance (BMS)
      • Janumet (Merck)
      • Jentadueto (Boehringer Ingelheim)
      • Kombiglyze XR (BMS)
      • Metaglip (BMS)
      • Prandimet (NovoNordisk)
  • Commercialized Drugs Not Approved by the FDA
    • Alpha-glucosidase Inhibitors
      • Basen (Voglibose)
      • Alogliptin
      • Galvus (Vildagliptin)
      • Nesina
  • Generic Non-Insulin Diabetes Management Drugs
  • Pipeline Candidates - Analysis and Prospects
    • Dipeptidyl peptidase IV
      • Dutogliptin (Phenomix)
      • Gemigliptin (LG Life Sciences)
    • Glucagon-Like Peptide-1 (GLP-1)
      • Lyxumia (Lixisenatide)
      • Syncria (GlaxoSmithKline)
    • Peroxisome Proliferator-activated Receptor agonist (PPAR)
      • Aleglitazar
    • SGLT2 Inhibitors
      • Dapagliflozin
      • Canagliflozin

Non-Insulin Diabetes Management - Market Segment Analysis & Forecasts

  • Analysis and Forecasts by Drug Class
  • Analysis and Forecasts by Region

Market Factors

  • Regulatory Factors
    • North America
    • European Union
    • Japan
  • Demographic Factors
  • Safety and Reporting
  • Patient Compliance Factors

Company Profiles

Show More
Pricing
Not Available
Get Notified
Email me when related reports are published